161 related articles for article (PubMed ID: 37357917)
1. The lipidomic profile of the nanoparticle-biomolecule corona reflects the diversity of plasma lipids.
Papafilippou L; Nicolaou A; Kendall AC; Camacho-Muñoz D; Hadjidemetriou M
Nanoscale; 2023 Jul; 15(26):11038-11051. PubMed ID: 37357917
[TBL] [Abstract][Full Text] [Related]
2. The biomolecule corona of lipid nanoparticles contains circulating cell-free DNA.
Gardner L; Warrington J; Rogan J; Rothwell DG; Brady G; Dive C; Kostarelos K; Hadjidemetriou M
Nanoscale Horiz; 2020 Nov; 5(11):1476-1486. PubMed ID: 32853302
[TBL] [Abstract][Full Text] [Related]
3. Proteomic and Lipidomic Analysis of Nanoparticle Corona upon Contact with Lung Surfactant Reveals Differences in Protein, but Not Lipid Composition.
Raesch SS; Tenzer S; Storck W; Rurainski A; Selzer D; Ruge CA; Perez-Gil J; Schaefer UF; Lehr CM
ACS Nano; 2015 Dec; 9(12):11872-85. PubMed ID: 26575243
[TBL] [Abstract][Full Text] [Related]
4. The Human In Vivo Biomolecule Corona onto PEGylated Liposomes: A Proof-of-Concept Clinical Study.
Hadjidemetriou M; McAdam S; Garner G; Thackeray C; Knight D; Smith D; Al-Ahmady Z; Mazza M; Rogan J; Clamp A; Kostarelos K
Adv Mater; 2019 Jan; 31(4):e1803335. PubMed ID: 30488990
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive analysis of liposomal biomolecular corona upon human plasma incubation: The evolution towards the lipid corona.
La Barbera G; Capriotti AL; Caracciolo G; Cavaliere C; Cerrato A; Montone CM; Piovesana S; Pozzi D; Quagliarini E; Laganà A
Talanta; 2020 Mar; 209():120487. PubMed ID: 31892008
[TBL] [Abstract][Full Text] [Related]
6. Nano-Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection.
Liu Y; Wang J; Xiong Q; Hornburg D; Tao W; Farokhzad OC
Acc Chem Res; 2021 Jan; 54(2):291-301. PubMed ID: 33180454
[TBL] [Abstract][Full Text] [Related]
7. Beyond the protein corona - lipids matter for biological response of nanocarriers.
Müller J; Prozeller D; Ghazaryan A; Kokkinopoulou M; Mailänder V; Morsbach S; Landfester K
Acta Biomater; 2018 Apr; 71():420-431. PubMed ID: 29524674
[TBL] [Abstract][Full Text] [Related]
8. In Vivo Biomolecule Corona around Blood-Circulating, Clinically Used and Antibody-Targeted Lipid Bilayer Nanoscale Vesicles.
Hadjidemetriou M; Al-Ahmady Z; Mazza M; Collins RF; Dawson K; Kostarelos K
ACS Nano; 2015 Aug; 9(8):8142-56. PubMed ID: 26135229
[TBL] [Abstract][Full Text] [Related]
9. Tuning liposome composition to modulate corona formation in human serum and cellular uptake.
Yang K; Mesquita B; Horvatovich P; Salvati A
Acta Biomater; 2020 Apr; 106():314-327. PubMed ID: 32081780
[TBL] [Abstract][Full Text] [Related]
10. Liposome protein corona characterization as a new approach in nanomedicine.
Capriotti AL; Cavaliere C; Piovesana S
Anal Bioanal Chem; 2019 Jul; 411(19):4313-4326. PubMed ID: 30758528
[TBL] [Abstract][Full Text] [Related]
11. In situ analysis of liposome hard and soft protein corona structure and composition in a single label-free workflow.
Kari OK; Ndika J; Parkkila P; Louna A; Lajunen T; Puustinen A; Viitala T; Alenius H; Urtti A
Nanoscale; 2020 Jan; 12(3):1728-1741. PubMed ID: 31894806
[TBL] [Abstract][Full Text] [Related]
12. In Situ Characterization of Protein Adsorption onto Nanoparticles by Fluorescence Correlation Spectroscopy.
Shang L; Nienhaus GU
Acc Chem Res; 2017 Feb; 50(2):387-395. PubMed ID: 28145686
[TBL] [Abstract][Full Text] [Related]
13. A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona.
Hadjidemetriou M; Al-Ahmady Z; Buggio M; Swift J; Kostarelos K
Biomaterials; 2019 Jan; 188():118-129. PubMed ID: 30343255
[TBL] [Abstract][Full Text] [Related]
14. PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions.
Hilvo M; Simolin H; Metso J; Ruuth M; Öörni K; Jauhiainen M; Laaksonen R; Baruch A
Atherosclerosis; 2018 Feb; 269():159-165. PubMed ID: 29366988
[TBL] [Abstract][Full Text] [Related]
15. Poly (N-vinylpyrrolidone) modification mitigates plasma protein corona formation on phosphomolybdate-based nanoparticles.
Yu Y; Ghalandari B; Shen G; Wang L; Liu X; Wang A; Li S; Xie H; Ding X
J Nanobiotechnology; 2021 Dec; 19(1):445. PubMed ID: 34949196
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Competition at the Nano-Bio Interface Enables Comprehensive Characterization of Protein Corona Dynamics and Deep Coverage of Proteomes.
Ferdosi S; Stukalov A; Hasan M; Tangeysh B; Brown TR; Wang T; Elgierari EM; Zhao X; Huang Y; Alavi A; Lee-McMullen B; Chu J; Figa M; Tao W; Wang J; Goldberg M; O'Brien ES; Xia H; Stolarczyk C; Weissleder R; Farias V; Batzoglou S; Siddiqui A; Farokhzad OC; Hornburg D
Adv Mater; 2022 Nov; 34(44):e2206008. PubMed ID: 35986672
[TBL] [Abstract][Full Text] [Related]
17. Effects of the protein corona on liposome-liposome and liposome-cell interactions.
Corbo C; Molinaro R; Taraballi F; Toledano Furman NE; Sherman MB; Parodi A; Salvatore F; Tasciotti E
Int J Nanomedicine; 2016; 11():3049-63. PubMed ID: 27445473
[TBL] [Abstract][Full Text] [Related]
18. Protein corona, understanding the nanoparticle-protein interactions and future perspectives: A critical review.
Kopac T
Int J Biol Macromol; 2021 Feb; 169():290-301. PubMed ID: 33340622
[TBL] [Abstract][Full Text] [Related]
19. Age and sex are associated with the plasma lipidome: findings from the GOLDN study.
Slade E; Irvin MR; Xie K; Arnett DK; Claas SA; Kind T; Fardo DW; Graf GA
Lipids Health Dis; 2021 Apr; 20(1):30. PubMed ID: 33812378
[TBL] [Abstract][Full Text] [Related]
20. Protein corona fingerprinting to differentiate sepsis from non-infectious systemic inflammation.
Papafilippou L; Claxton A; Dark P; Kostarelos K; Hadjidemetriou M
Nanoscale; 2020 May; 12(18):10240-10253. PubMed ID: 32356537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
